Andreas Brückner

Safety and Tolerability of Acarbose in the Treatment of Type 1 and Type 2 Diabetes Mellitus

B. Hoogwerf, R. Goldberg, D. Petzinna, 2005, Clinical drug investigation.

Survival analysis for AdVerse events with VarYing follow-up times (SAVVY)—estimation of adverse event risks

K. Rufibach, T. Friede, C. Schmoor, 2020, Trials.

Long-Term Efficacy and Tolerability of Acarbose Treatment in Patients with Type 2 Diabetes Mellitus

P. Segal, D. Petzinna, M. Spengler, 2005, Clinical drug investigation.

Development and validation of a risk-score model for subjects with impaired glucose tolerance for the assessment of the risk of type 2 diabetes mellitus-The STOP-NIDDM risk-score.

Martin Hellmich, Qing Qiao, Jaakko Tuomilehto, 2010, Diabetes research and clinical practice.

Gastrointestinal Adverse Effects of Short-Term Aspirin Use: A Meta-Analysis of Published Randomized Controlled Trials

Stephen Senn, Michael Voelker, Angel Lanas, 2013, Drugs in R&D.

Survival analysis for AdVerse events with VarYing follow-up times (SAVVY)—estimation of adverse event risks

K. Rufibach, T. Friede, C. Schmoor, 2020, Trials.